On February 20, 2007, the Food and Drug Administration requested that Genentech submit draft labeling incorporating a boxed warning and other changes in the Xolair package insert. The labeling would provide additional information to practitioners and patients of the potential risk of anaphylaxis associated with the administration of Xolair.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.